Feb 16 |
Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript
|
Feb 15 |
Travere Therapeutics Non-GAAP EPS of $0.94 beats by $1.86, revenue of $45.05M beats by $3.23M
|
Feb 15 |
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|
Feb 14 |
Travere Therapeutics Q4 2023 Earnings Preview
|
Feb 8 |
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
|
Feb 1 |
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
|
Jan 30 |
Travere Therapeutics: Restructuring Away From Disaster
|
Jan 25 |
Travere inks licensing deal for sparsentan in Asia
|
Jan 25 |
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
|
Jan 18 |
Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics
|